Lv61
2319 积分 2021-12-14 加入
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial
21天前
已完结
Abstract 7025: Mechanisms of zongertinib resistance in HER2-mutant non-small cell lung cancer and potential strategies to overcome resistance
21天前
已关闭
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
2个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
2个月前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
2个月前
已完结
Vorasidenib: a new hope or a false promise for patients with low-grade glioma?
3个月前
已完结
Hodgkin lymphoma: great progress with room for improvement
3个月前
已完结
Personalizing adjuvant therapy for patients with colorectal cancer
3个月前
已完结
T-DXd plus pertuzumab effective as first-line therapy
3个月前
已完结
Vebreltinib effective in MET-amplified NSCLC
3个月前
已完结
皖公网安备34019202002308
